Clinical Trial Update: SUBLIVAC FIX Birch Phase III Short-term Efficacy [Phase 3]

View source ↗

Summary

Phase III trial assessing the short-term efficacy of SUBLIVAC FIX Birch for Birch pollen-induced rhinoconjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Birch Pollen-induced Rhinoconjunctivitis

Drugs mentioned

• SUBLIVAC FIX Birch (birch pollen allergen extract)

Snippet

Sponsor: HAL Allergy | Conditions: Birch Pollen Induced Rhinitis/Rhinoconjunctivitis | Phase 3 | Status: COMPLETED